Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 5.897
Filter
1.
BMC Infect Dis ; 24(1): 906, 2024 Sep 02.
Article in English | MEDLINE | ID: mdl-39223521

ABSTRACT

BACKGROUND: Glycopeptides for ampicillin-susceptible Enterococcus faecalis/faecium bacteremia are readily prescribed depending on the severity of the condition. However, there is limited data on the outcomes of glycopeptide use compared to ampicillin-containing regimens for ampicillin-susceptible E. faecalis/faecium bacteremia. From an antibiotic stewardship perspective, it is important to determine whether the use of glycopeptides is associated with improved clinical outcomes in patients with ampicillin-susceptible E. faecalis/faecium bacteremia. METHODS: This retrospective cohort study was conducted at a university-affiliated hospital between January 2010 and September 2019. We collected data from patients with positive blood cultures for Enterococcus species isolates. The clinical data of patients who received ampicillin-containing regimens or glycopeptides as definitive therapy for ampicillin-susceptible E. faecalis/faecium bacteremia were reviewed. Multivariate logistic regression analysis was performed to identify risk factors for 28-day mortality. RESULTS: Ampicillin-susceptible E. faecalis/faecium accounted for 41.2% (557/1,353) of enterococcal bacteremia cases during the study period. A total of 127 patients who received ampicillin-containing regimens (N = 56) or glycopeptides (N = 71) as definitive therapy were included in the analysis. The 28-day mortality rate was higher in patients treated with glycopeptides (19.7%) than in those treated with ampicillin-containing regimens (3.6%) (p = 0.006). However, in the multivariate model, antibiotic choice was not an independent predictor of 28-day mortality (adjusted OR, 3.7; 95% CI, 0.6-23.6). CONCLUSIONS: Glycopeptide use was not associated with improved mortality in patients with ampicillin-susceptible E. faecalis/faecium bacteremia. This study provides insights to reduce the inappropriate use of glycopeptides in ampicillin-susceptible E. faecalis/faecium bacteremia treatment and promote antimicrobial stewardship.


Subject(s)
Ampicillin , Anti-Bacterial Agents , Bacteremia , Enterococcus faecalis , Glycopeptides , Gram-Positive Bacterial Infections , Sulbactam , Humans , Retrospective Studies , Bacteremia/drug therapy , Bacteremia/microbiology , Bacteremia/mortality , Ampicillin/therapeutic use , Ampicillin/pharmacology , Male , Female , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Enterococcus faecalis/drug effects , Gram-Positive Bacterial Infections/drug therapy , Gram-Positive Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/mortality , Aged , Middle Aged , Glycopeptides/therapeutic use , Glycopeptides/pharmacology , Sulbactam/therapeutic use , Sulbactam/pharmacology , Treatment Outcome , Microbial Sensitivity Tests , Aged, 80 and over
2.
Pharmacol Res Perspect ; 12(4): e1250, 2024 Aug.
Article in English | MEDLINE | ID: mdl-39105353

ABSTRACT

Sepsis is a common disease with high morbidity and mortality among newborns in intensive care units world-wide. Gram-negative bacillary bacteria are the major source of infection in neonates. Gentamicin is the most widely used aminoglycoside antibiotic in empiric therapy against early-onset sepsis. However, therapy failure may result due to various factors. The purpose of this study was to identify predictors of gentamicin therapy failure in neonates with sepsis. This was a prospective cross-sectional study at the Neonatal Intensive Care Unit at Windhoek Central Hospital over a period of 5 months in 2019. Neonates received intravenous gentamicin 5 mg/kg/24 h in combination with either benzylpenicillin 100 000 IU/kg/12 h or ampicillin 50 mg/kg/8 h. Logistic regression modeling was performed to determine the predictors of treatment outcomes. 36% of the 50 neonates were classified as having gentamicin treatment failure. Increasing treatment duration by 1 day resulted in odds of treatment failure increasing from 1.0 to 2.41. Similarly, one unit increase in CRP increases odds of gentamicin treatment failure by 49%. The 1 kg increase in birthweight reduces the log odds of treatment failure by 6.848, resulting in 99.9% decrease in the odds of treatment failure. One unit increase in WBC reduces odds of gentamicin treatment failure by 27%. Estimates of significant predictors of treatment failure were precise, yielding odds ratios that were within 95% confidence interval. This study identified the following as predictors of gentamicin therapy failure in neonates: prolonged duration of treatment, elevated C-reactive protein, low birthweight, and low white blood cell count.


Subject(s)
Anti-Bacterial Agents , Gentamicins , Intensive Care Units, Neonatal , Treatment Failure , Humans , Gentamicins/therapeutic use , Gentamicins/administration & dosage , Infant, Newborn , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/administration & dosage , Cross-Sectional Studies , Prospective Studies , Female , Male , Intensive Care Units, Neonatal/statistics & numerical data , Neonatal Sepsis/drug therapy , C-Reactive Protein/analysis , Sepsis/drug therapy , Sepsis/mortality , Birth Weight , Ampicillin/therapeutic use , Ampicillin/administration & dosage
3.
Medicine (Baltimore) ; 103(31): e39015, 2024 Aug 02.
Article in English | MEDLINE | ID: mdl-39093751

ABSTRACT

RATIONALE: Listeria monocytogenes (LM) is an important foodborne bacterium, and LM meningoencephalitis is rare in clinical practice, with poor prognosis in severe patients. It is prone to misdiagnosis in clinical practice. We first reported a case of severe LM meningoencephalitis with muscle lesions and evaluated the comprehensive condition. PATIENT CONCERNS: A 48-year-old man had a fever and was admitted to the neurology department due to dizziness, nausea, and vomiting for 20 days. DIAGNOSES: LM meningoencephalitis complicated with muscle lesions. INTERVENTIONS: We used moxifloxacin 0.4 g, qd, meropenem 2 g, q8h, and dexamethasone 10 mg, qd to reduce exudation and adhesion. Then due to consideration of side effects, we increased the dose of ampicillin by 2 g, q4h, stopped using meropenem and moxifloxacin, and turned to maintenance treatment with dexamethasone and ampicillin. We comprehensively managed his vital signs and physical organ functions, we also controlled some comorbidities. During the hospitalization period thereafter, we used intravenous anti-infection treatment with moxifloxacin 0.4 g, qd, ampicillin 0.5 g, q4h. OUTCOMES: Half a year later, the reexamination showed only protein elevation in cerebrospinal fluid and hydrocephalus in MRI. Afterward, the symptoms did not recur again. The patient recovered well after discharge. LESSONS: LM meningoencephalitis complicated with lower limb muscle lesions is clinically rare. This report focuses on relevant treatment plans, which provide value for the examination and comprehensive management of patients with LM infection in the future.


Subject(s)
Anti-Bacterial Agents , Dizziness , Fever , Nausea , Vomiting , Humans , Male , Middle Aged , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/administration & dosage , Fever/etiology , Dizziness/etiology , Vomiting/etiology , Nausea/etiology , Meningoencephalitis/drug therapy , Meningoencephalitis/diagnosis , Meningoencephalitis/microbiology , Moxifloxacin/therapeutic use , Moxifloxacin/administration & dosage , Dexamethasone/therapeutic use , Dexamethasone/administration & dosage , Listeria monocytogenes/isolation & purification , Ampicillin/therapeutic use , Ampicillin/administration & dosage
4.
Arch Gynecol Obstet ; 310(4): 1951-1957, 2024 Oct.
Article in English | MEDLINE | ID: mdl-39093332

ABSTRACT

PURPOSE: Meconium-stained amniotic fluid (MSAF) often signifies colonization of the amniotic sac by microorganisms. This study investigated additional adverse obstetric outcomes associated with MSAF in deliveries complicated by maternal intrapartum fever (IF). METHODS: This retrospective study included all singleton pregnancies from 2014 to 2020, with intrapartum maternal fever ≥ 38 °C during a trial of labor. In accordance with departmental protocol, all patients received intravenous antibiotic therapy consisting of ampicillin and gentamicin in the absence of allergies to these medications. Subsequent antibiotic therapy was adjusted based on the culture results. Antibiotic treatment was discontinued postpartum after 48 h without fever. Swab cultures were obtained immediately postpartum from both the maternal and fetal sides of the placenta. Maternal and fetal outcomes, along with positive placental cultures, were compared between participants with MSAF&IF and those with clear amniotic fluid &IF (control group). RESULTS: In comparison to the control group (n = 1089), the MSAF&IF group (n = 264) exhibited significantly higher rates of cesarean delivery (CD) (p = 0.001), CD due to non-reassuring fetal heart rate (p = 0.001), and cord pH ≤ 7.1 (p = 0.004). Positive swab cultures from the placental maternal and fetal sides were more prevalent among the MSAF&IF group (23.1% vs. 17.6%, p = 0.041 and 29.2% vs. 22.9%, p = 0.032, respectively). Placental cultures yielding gastrointestinal pathogens and extended spectrum beta-lactamase were notably more common in the MSAF&IF group compared to controls (p = 0.023). However, there was no significant difference between groups regarding the rate of group B streptococcus positive placental cultures. CONCLUSIONS: Women experiencing IF and MSAF during labor face an elevated risk of CD compared to those with IF alone. The presence of MSAF heightens the risk of positive placental cultures, particularly with gastrointestinal and extended spectrum beta-lactamase pathogens.


Subject(s)
Amniotic Fluid , Anti-Bacterial Agents , Cesarean Section , Meconium , Humans , Female , Pregnancy , Meconium/microbiology , Retrospective Studies , Amniotic Fluid/microbiology , Adult , Cesarean Section/statistics & numerical data , Anti-Bacterial Agents/therapeutic use , Infant, Newborn , Fever , Placenta/microbiology , Ampicillin/therapeutic use , Pregnancy Complications, Infectious/microbiology , Pregnancy Complications, Infectious/diagnosis , Gentamicins/therapeutic use , Pregnancy Outcome , Obstetric Labor Complications/microbiology , Obstetric Labor Complications/diagnosis , Obstetric Labor Complications/etiology
5.
J Med Case Rep ; 18(1): 390, 2024 Aug 23.
Article in English | MEDLINE | ID: mdl-39175052

ABSTRACT

BACKGROUND: Listeria monocytogenes brain abscess is a rare phenomenon that is common in immunocompromised patients. Streptococcus equinus brain abscess has never been reported in the literature to our knowledge. In this case report, we describe a case of brain abscess secondary to Listeria monocytogenes and Streptococcus equinus in an immunocompetent patient with transient low CD4 count. CASE PRESENTATION: A 27-year-old white, male patient, previously healthy, nonalcoholic, and occasional smoker, presented to the emergency department for confusion and headache. The patient was found to have a left parietal abscess, which was drained and the fluid was sent for culture. Culture grew Listeria monocytogenes and Streptococcus equinus. The patient was treated with intravenous ampicillin followed by oral amoxicillin for a total of 6 weeks. The CD4 count was low initially. However, after the resolution of the infection, the CD4 count came back within normal range. Another brain magnetic resonance imaging was done that showed a significantly decreased hyperintensity within the left parietal subcortical white matter at the site of surgery with significantly decreased enhancement and almost total resolution of the previous abscess. CONCLUSION: Transient low CD4 count is a rare phenomenon that exposes patients to unusual and atypical infections. Since low CD4 count is transient, patients treated promptly recover from their illness. Our patient developed a Listeria monocytogenes and Streptococcus equinus brain abscess, which is considered rare and has not been previously described in the literature to our knowledge.


Subject(s)
Anti-Bacterial Agents , Brain Abscess , Listeria monocytogenes , Listeriosis , Streptococcal Infections , Humans , Male , Brain Abscess/microbiology , Brain Abscess/drug therapy , Listeria monocytogenes/isolation & purification , Adult , Anti-Bacterial Agents/therapeutic use , Streptococcal Infections/drug therapy , Streptococcal Infections/microbiology , Streptococcal Infections/diagnosis , Listeriosis/drug therapy , Listeriosis/diagnosis , Listeriosis/microbiology , Magnetic Resonance Imaging , Ampicillin/therapeutic use , Immunocompetence , Amoxicillin/therapeutic use , Amoxicillin/administration & dosage
6.
PLoS One ; 19(7): e0304705, 2024.
Article in English | MEDLINE | ID: mdl-38980858

ABSTRACT

This is a protocol for PPROM-AZM Study, phase II, nonblinded, randomized controlled trial. Bronchopulmonary dysplasia (BPD) at a postmenstrual age of 36 weeks (BPD36) is often observed in infants with preterm premature rupture of the membranes (pPROM). A regimen of ampicillin (ABPC) intravenous infusion for 2 days and subsequent amoxicillin (AMPC) oral administration for 5 days plus erythromycin (EM) intravenous infusion for 2 days followed by EM oral administration for 5 days is standard treatment for pPROM. However, the effect on the prevention of moderate/severe BPD36 using the standard treatment has not been confirmed. Recently, it is reported that ampicillin/sulbactam (ABPC/SBT) plus azithromycin (AZM) was effective for the prevention of moderate/severe BPD36 in pPROM patients with amniotic infection of Ureaplasma species. Therefore, our aim is to evaluate the occurrence rate of the composite outcome of "incidence rate of either moderate/severe BPD36 or intrauterine fetal death, and infantile death at or less than 36 weeks 0 days" comparing subjects to receive ABPC/SBT for 14 days plus AZM for 14 days (intervention group) and those to receive ABPC/SBT for 14 days plus EM for 14 days (control group), in a total of 100 subjects (women with pPROM occurring at 22-27 weeks of gestation) in Japan. The recruit of subjects was started on April 2022, and collection in on-going. We also investigate the association between the detection of Ureaplasma species and occurrence of BPD36. In addition, information on any adverse events for the mother and fetus and serious adverse events for infants are collected during the observation period. We allocate patients at a rate of 1:1 considering two stratification factors: onset of pPROM (22-23 or 24-27 weeks) and presence/absence of a hospital policy for early neonatal administration of caffeine. Trial registration: The trial number in the Japan Registry of Clinical Trials is jRCTs031210631.


Subject(s)
Ampicillin , Anti-Bacterial Agents , Azithromycin , Bronchopulmonary Dysplasia , Erythromycin , Fetal Membranes, Premature Rupture , Adult , Female , Humans , Infant, Newborn , Pregnancy , Amoxicillin/therapeutic use , Amoxicillin/administration & dosage , Ampicillin/administration & dosage , Ampicillin/therapeutic use , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Azithromycin/administration & dosage , Azithromycin/therapeutic use , Bronchopulmonary Dysplasia/prevention & control , Bronchopulmonary Dysplasia/drug therapy , Drug Therapy, Combination , Erythromycin/therapeutic use , Erythromycin/administration & dosage , Fetal Membranes, Premature Rupture/drug therapy , Gestational Age , Japan/epidemiology , Sulbactam/administration & dosage , Sulbactam/therapeutic use , Randomized Controlled Trials as Topic , Multicenter Studies as Topic , Clinical Trials, Phase II as Topic
7.
Surg Infect (Larchmt) ; 25(7): 553-557, 2024 Sep.
Article in English | MEDLINE | ID: mdl-38958001

ABSTRACT

Background: The optimal ampicillin-sulbactam dosing regimen for carbapenem-susceptible Acinetobacter baumannii isolates in critically ill trauma patients has not been clearly defined. One strategy to provide the adequate sulbactam dose includes high-dose continuous infusion. Case(s) Description: We present three cases of critically ill trauma patients with augmented renal clearance treated with high-dose ampicillin-sulbactam through an intravenous continuous infusion for ventilator-associated pneumonia. All A. baumannii isolates were susceptible to sulbactam with low minimum inhibitory concentrations. All achieved clinical cure at the end of therapy and no recurrent pneumonia was noted. No clinically substantial adverse effect attributable to ampicillin-sulbactam therapy occurred. Discussion: There is limited evidence to endorse high-dose, continuous infusion ampicillin-sulbactam for treatment of infections caused by carbapenem-susceptible A. baumannii. This report presents three critically ill trauma patients with augmented renal clearance that achieved positive clinical outcomes with higher doses of ampicillin-sulbactam administered through a continuous infusion.


Subject(s)
Acinetobacter Infections , Acinetobacter baumannii , Ampicillin , Anti-Bacterial Agents , Intensive Care Units , Sulbactam , Humans , Acinetobacter baumannii/drug effects , Sulbactam/administration & dosage , Sulbactam/therapeutic use , Ampicillin/administration & dosage , Ampicillin/therapeutic use , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Male , Acinetobacter Infections/drug therapy , Acinetobacter Infections/microbiology , Middle Aged , Adult , Carbapenems/administration & dosage , Carbapenems/pharmacology , Female , Microbial Sensitivity Tests , Infusions, Intravenous , Pneumonia, Ventilator-Associated/drug therapy , Pneumonia, Ventilator-Associated/microbiology , Treatment Outcome , Critical Illness , Wounds and Injuries/complications , Wounds and Injuries/drug therapy , Wounds and Injuries/microbiology , Aged
8.
J Infect Chemother ; 30(11): 1186-1189, 2024 Nov.
Article in English | MEDLINE | ID: mdl-38901745

ABSTRACT

Urinary tract infections caused by Aerococcus urinae have rarely been reported in children, and the clinical characteristics remain unclear. We reviewed medical records of children whose urine cultures grew A. urinae (≥104 CFU/mL) at a tertiary children's hospital in Tokyo, Japan. We found 17 pediatric patients in a review of 22,769 urine cultures between June 2006 and May 2022. The median age of 17 patients was 10.7 years (IQR 8-13 years), and males represented 76.5 % of the patients. Sixteen patients (94.1 %) had underlying urological conditions (neurogenic bladder, vesicoureteral reflux, urethral stenosis, bladder exstrophy, or urinary catheterization). The chief symptoms were fever (35.3 %), malodorous urine (23.5 %), nausea (11.8 %), and back pain (5.9 %). Ten patients were asymptomatic. Pyelonephritis was diagnosed in five male patients. All of them had underlying abnormal conditions of the bladder, and two had malodorous urine. All patients had favorable outcomes after 10-14 days of ampicillin/amoxicillin-based antimicrobial therapy.


Subject(s)
Aerococcus , Anti-Bacterial Agents , Urinary Tract Infections , Humans , Male , Urinary Tract Infections/microbiology , Urinary Tract Infections/drug therapy , Urinary Tract Infections/diagnosis , Urinary Tract Infections/urine , Aerococcus/isolation & purification , Aerococcus/drug effects , Female , Child , Adolescent , Anti-Bacterial Agents/therapeutic use , Retrospective Studies , Gram-Positive Bacterial Infections/urine , Gram-Positive Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/diagnosis , Gram-Positive Bacterial Infections/drug therapy , Pyelonephritis/microbiology , Pyelonephritis/urine , Pyelonephritis/drug therapy , Pyelonephritis/diagnosis , Ampicillin/therapeutic use , Japan/epidemiology , Amoxicillin/therapeutic use
10.
Biomater Adv ; 162: 213931, 2024 Sep.
Article in English | MEDLINE | ID: mdl-38924805

ABSTRACT

Microbial colonization and development of infections in wounds is a sign of chronicity. The prevailing approach to manage and treat these wounds involves dressings. However, these often fail in effectively addressing infections, as they struggle to both absorb exudates and maintain optimal local moisture. The system here presented was conceptualized with a three-layer design: the outer layer made of a fibrous polycaprolactone (PCL) film, to act as a barrier for preventing microorganisms and impurities from reaching the wound; the intermediate layer formed of a sodium alginate (SA) hydrogel loaded with ampicillin (Amp) for fighting infections; and the inner layer comprised of a fibrous film of PCL and polyethylene glycol (PEG) for facilitating cell recognition and preventing wound adhesion. Thermal evaluations, degradation, wettability and release behavior testing confirmed the system resistance overtime. The sandwich demonstrated the capability for absorbing exudates (≈70 %) and exhibited a controlled release of Amp for up to 24 h. Antimicrobial testing was performed against Staphylococcus aureus and Escherichia coli, as representatives of Gram-positive and Gram-negative bacteria: >99 % elimination of bacteria. Cell cytotoxicity assessments showed high cytocompatibility levels, confirming the safety of the proposed sandwich system. Adhesion assays confirmed the system ease of detaching without mechanical effort (0.37 N). Data established the efficiency of the sandwich-like system, suggesting promising applications in infected wound care.


Subject(s)
Alginates , Anti-Bacterial Agents , Escherichia coli , Polyesters , Staphylococcus aureus , Wound Infection , Alginates/chemistry , Wound Infection/drug therapy , Wound Infection/microbiology , Staphylococcus aureus/drug effects , Escherichia coli/drug effects , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/administration & dosage , Polyesters/chemistry , Ampicillin/pharmacology , Ampicillin/therapeutic use , Ampicillin/chemistry , Humans , Hydrogels/chemistry , Polyethylene Glycols/chemistry , Animals , Bandages , Microbial Sensitivity Tests , Mice , Wound Healing/drug effects
11.
Int J Antimicrob Agents ; 64(1): 107190, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38697579

ABSTRACT

BACKGROUND: Severe infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) have been reported increasingly over the past few years. Many in-vivo and in-vitro studies have suggested a possible role of intravenous fosfomycin for the treatment of CRAB infections. METHODS: This multi-centre, retrospective study included patients treated with intravenous fosfomycin for severe infections caused by CRAB admitted consecutively to four hospitals in Italy from December 2017 to December 2022. The primary goal of the study was to evaluate the risk factors associated with 30-day mortality in the study population. A propensity score matched analysis was added to the model. RESULTS: One hundred and two patients with severe infections caused by CRAB treated with an intravenous fosfomycin-containing regimen were enrolled in this study. Ventilator-associated pneumonia (VAP) was diagnosed in 59% of patients, primary bacteraemia in 22% of patients, and central-venous-catheter-related infection in 16% of patients. All patients were treated with a regimen containing intravenous fosfomycin, mainly in combination with cefiderocol (n=54), colistin (n=48) or ampicillin/sulbactam (n=18). Forty-eight (47%) patients died within 30 days. Fifty-eight (57%) patients experienced clinical therapeutic failure. Cox regression analysis showed that diabetes, primary bacteraemia and a colistin-containing regimen were independently associated with 30-day mortality, whereas adequate source control of infection, early 24-h active in-vitro therapy, and a cefiderocol-containing regimen were associated with survival. A colistin-based regimen, A. baumannii colonization and primary bacteraemia were independently associated with clinical failure. Conversely, adequate source control of infection, a cefiderocol-containing regimen, and early 24-h active in-vitro therapy were associated with clinical success. CONCLUSIONS: Different antibiotic regimens containing fosfomycin in combination can be used for treatment of severe infections caused by CRAB.


Subject(s)
Acinetobacter Infections , Acinetobacter baumannii , Administration, Intravenous , Anti-Bacterial Agents , Carbapenems , Fosfomycin , Pneumonia, Ventilator-Associated , Sulbactam , Humans , Fosfomycin/therapeutic use , Fosfomycin/administration & dosage , Acinetobacter baumannii/drug effects , Acinetobacter Infections/drug therapy , Acinetobacter Infections/mortality , Acinetobacter Infections/microbiology , Retrospective Studies , Male , Female , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/administration & dosage , Aged , Middle Aged , Carbapenems/therapeutic use , Sulbactam/therapeutic use , Sulbactam/administration & dosage , Pneumonia, Ventilator-Associated/drug therapy , Pneumonia, Ventilator-Associated/microbiology , Pneumonia, Ventilator-Associated/mortality , Colistin/therapeutic use , Colistin/administration & dosage , Italy , Ampicillin/therapeutic use , Ampicillin/administration & dosage , Cefiderocol , Aged, 80 and over , Drug Therapy, Combination , Bacteremia/drug therapy , Bacteremia/microbiology , Bacteremia/mortality , Drug Resistance, Multiple, Bacterial
12.
Acta Paediatr ; 113(7): 1694-1700, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38578153

ABSTRACT

AIM: To compare the prophylactic efficacy of ampicillin and clindamycin against vertical transmission of group B Streptococcus from mothers to their infants by evaluating the rates of group B Streptococcus colonisation. METHODS: We retrospectively extracted data for mothers who delivered at Showa University Northern Yokohama Hospital between 1 October 2017 and 31 March 2021 and tested positive for antepartum group B Streptococcus, and their infants. The chi-square test was used to compare the rates of group B Streptococcus colonisation, sepsis, and meningitis. We conducted a multivariate logistic regression analysis, including the time interval between membrane rupture and delivery, chorioamnionitis, and maternal intrapartum fever (≥38.0°C). RESULTS: Two hundred fifty-nine mothers and their infants were eligible. Ampicillin and clindamycin were administered to 150 and 109 mothers, respectively. In the ampicillin and clindamycin groups, 12.0% (18/150) and 37.6% (41/109) infants were group B Streptococcus positive, respectively. The rate of group B Streptococcus colonisation among infants was significantly lower in the ampicillin group (p < 0.001). Multivariate regression analysis showed similar results (p < 0.001). No sepsis or meningitis cases were observed in either group. CONCLUSION: Prophylactic efficacy of clindamycin against the vertical transmission of group B Streptococcus is lower than that of ampicillin.


Subject(s)
Ampicillin , Anti-Bacterial Agents , Clindamycin , Infectious Disease Transmission, Vertical , Streptococcal Infections , Streptococcus agalactiae , Humans , Ampicillin/therapeutic use , Clindamycin/therapeutic use , Female , Infectious Disease Transmission, Vertical/prevention & control , Retrospective Studies , Streptococcal Infections/prevention & control , Streptococcal Infections/transmission , Pregnancy , Anti-Bacterial Agents/therapeutic use , Infant, Newborn , Adult , Antibiotic Prophylaxis/methods , Pregnancy Complications, Infectious/prevention & control , Pregnancy Complications, Infectious/drug therapy
13.
Inn Med (Heidelb) ; 65(5): 512-516, 2024 May.
Article in German | MEDLINE | ID: mdl-38459199

ABSTRACT

BACKGROUND: Rat bite fever is a rare but potentially fatal bacterial zoonosis. The symptoms can be unspecific, but severe sepsis can be associated with involvement of different organs. CASE REPORT: A 27-year-old homeless man presented with fever, suspected meningitis, acute renal failure, unclear skin lesions as well as joint problems and muscular pain. Bite wounds were not detected. Meningitis could be excluded after lumbar puncture, and there was no evidence of endocarditis as the cause of the skin lesions. After 72 h, growth of Streptobacillus moniliformis in blood cultures was detected. Clinical symptoms were compatible with the diagnosis of rat bite fever. Calculated antibiosis with ampicillin sulbactam and doxycycline led to regression of the symptoms. CONCLUSION: Rat bite fever poses a diagnostic challenge due unspecific symptoms, diverse differential diagnostic options, and challenging microbiological detection. Patient history is of the utmost importance. Due to the rarity of the disease, this case report is intended to raise awareness.


Subject(s)
Rat-Bite Fever , Streptobacillus , Zoonoses , Male , Adult , Rat-Bite Fever/diagnosis , Rat-Bite Fever/drug therapy , Rat-Bite Fever/microbiology , Humans , Animals , Streptobacillus/isolation & purification , Zoonoses/diagnosis , Zoonoses/microbiology , Zoonoses/transmission , Anti-Bacterial Agents/therapeutic use , Doxycycline/therapeutic use , Diagnosis, Differential , Rats , Sulbactam/therapeutic use , Sulbactam/administration & dosage , Ampicillin/therapeutic use
14.
Infection ; 52(4): 1621-1625, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38488973

ABSTRACT

INTRODUCTION: Haemophilus influenzae (HI) is an exceedingly rare cause of infective endocarditis (IE). CASE PRESENTATION/METHODS: We present a case of a 90-year-old female diagnosed with HI-IE involving the native tricuspid valve in the absence of traditional risk factors for right-sided endocarditis. She was treated with a 5-week course of IV Ampicillin from negative cultures and suffered no complications. We also conducted a thorough literature review through PubMed and Google Scholar, which yielded a mere 15 reported cases of HI-IE. RESULTS: Fourteen of the reported HI-IE cases included epidemiological data, showing no gender predominance. The mean age of the subjects was 39.5, with the mitral valve being the most implicated (64%) and tricuspid valve involvement being rare (21%). CONCLUSION: Native tricuspid valve IE is an uncommon entity, especially in the absence of IV drug use. Haemophilus influenzae is an extremely rare cause of IE, with a literature review showing merely 15 reported cases. This article cites the 16th case of HI-IE published in the literature.


Subject(s)
Anti-Bacterial Agents , Endocarditis, Bacterial , Haemophilus Infections , Haemophilus influenzae , Humans , Female , Haemophilus Infections/drug therapy , Haemophilus Infections/microbiology , Haemophilus Infections/diagnosis , Aged, 80 and over , Haemophilus influenzae/isolation & purification , Anti-Bacterial Agents/therapeutic use , Endocarditis, Bacterial/microbiology , Endocarditis, Bacterial/drug therapy , Endocarditis, Bacterial/diagnosis , Ampicillin/therapeutic use , Tricuspid Valve/microbiology , Tricuspid Valve/diagnostic imaging
15.
J Infect Dev Ctries ; 18(2): 219-226, 2024 Feb 29.
Article in English | MEDLINE | ID: mdl-38484340

ABSTRACT

OBJECTIVE: To investigate the clinical characteristics and prognostic risk factors for Klebsiella pneumoniae bloodstream infections in immunocompetent patients. METHODS: The study included patients with K. pneumoniae bloodstream infection treated in Zhongda Hospital from June 2016 to June 2021. Clinical data and antibiotic susceptibility test results were retrospectively collected and analyzed. Independent risk factors for mortality were screened using the chi-square test and multivariate logistic regression. RESULTS: A total of 152 patients were included in the analysis. In our cohort, 77.6% of patients were older than 60 years, and 80.9% of them had community-acquired infections. The most common complications were type 2 diabetes, hypertension, and stroke sequelae. The proportion of patients with septic shock or abscesses was 34.9% and 25.7%, respectively. There were significant differences in the site of infection, septic shock, and serum levels of procalcitonin, hypersensitive C-reactive protein, D-dimer, creatinine, and lactic acid between survivors and non-survivors (p < 0.05). Multivariate regression analysis showed that hospital-acquired infections, septic shock, length of hospital stay, and creatinine levels were independent risk factors for mortality. Antibiotic susceptibility test results indicated that clinical outcomes varied depending on bacterial sensitivity to ampicillin/sulbactam. DISCUSSION: Klebsiella pneumoniae is a common community-acquired and hospital-acquired bacteria and usually infects older people with complications such as diabetes. Nosocomial infections, length of stay, septic shock, and renal insufficiency are potentially associated with poor prognosis. Bacterial susceptibility to ampicillin/sulbactam affects prognosis.


Subject(s)
Bacteremia , Cross Infection , Diabetes Mellitus, Type 2 , Klebsiella Infections , Sepsis , Shock, Septic , Humans , Aged , Klebsiella pneumoniae , Retrospective Studies , Sulbactam/therapeutic use , Creatinine , Bacteremia/microbiology , Klebsiella Infections/microbiology , Risk Factors , Anti-Bacterial Agents/therapeutic use , Cross Infection/microbiology , Sepsis/drug therapy , Ampicillin/therapeutic use
16.
J Infect Dev Ctries ; 18(2): 227-234, 2024 Feb 29.
Article in English | MEDLINE | ID: mdl-38484341

ABSTRACT

INTRODUCTION: Extensively drug resistant (XDR) strains of the Salmonella lineages have been reported to spread from Africa to South Asia. XDR strains are resistant to fluoroquinolones, chloramphenicol, co-trimoxazole, and ampicillin, resulting in treatment failure. The objectives of this study included the investigation of transmission of S. Typhi lineages and the identification of the potentially contaminated sources of the XDR typhoid outbreak from different urban areas by using molecular techniques. METHODOLOGY: Environmental samples, including food samples, were collected from different towns and the susceptibility of each isolate to the antimicrobial agents was examined. Molecular identification of different Salmonella lineages including S. Typhi, S. Paratyphi A, H58, and XDR was carried out through multiplex PCR. RESULTS AND CONCLUSIONS: A total of 328 environmental samples including raw vegetables, water, and bakery items were collected. More than half of the tested samples (64%) found harboring Salmonella spp. The Salmonella was confirmed through PCR amplification of species-specific markers that showed the presence of S. Typhi (40%), S. Paratyphi A (8%), H58 (7%), and XDR S. Typhi (6%). Raw vegetables had the highest number of Salmonella spp., indicating consumption of raw vegetables as a possible source of salmonellosis. XDR status was also affirmed through phenotypic antimicrobial susceptibility testing.


Subject(s)
Salmonella typhi , Typhoid Fever , Vegetables , Typhoid Fever/epidemiology , Typhoid Fever/drug therapy , Ampicillin/therapeutic use , Chloramphenicol/therapeutic use , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Drug Resistance, Bacterial
17.
Clin Lab ; 70(3)2024 Mar 01.
Article in English | MEDLINE | ID: mdl-38469790

ABSTRACT

BACKGROUND: This case involves a 28-year-old pregnant woman (39w+2) who was admitted to obstetrics due to abdominal tightness and bacteremia with Gardnerella vaginalis which developed after caesarean section and vaginal myomectomy. METHODS: A blood culture was performed, and the bacteria were identified through mass spectrometry. RESULTS: Mass spectrometry data indicated that the infection bacteria were Gardnerella vaginalis. The patient's temperature returned to normal after oral ampicillin in combination with clindamycin. CONCLUSIONS: Gardnerella vaginalis bacteremia is very rare in clinical practice, and the combination of ampicillin and clindamycin has a good therapeutic effect. This study may provide a reference for the diagnosis and treatment of Gardnerella vaginalis bacteremia.


Subject(s)
Bacteremia , Uterine Myomectomy , Vaginosis, Bacterial , Female , Pregnancy , Humans , Adult , Gardnerella vaginalis , Pregnant Women , Clindamycin/therapeutic use , Cesarean Section/adverse effects , Ampicillin/therapeutic use , Bacteremia/diagnosis , Bacteremia/drug therapy , Bacteremia/microbiology , Vaginosis, Bacterial/drug therapy , Vagina
18.
J Antimicrob Chemother ; 79(4): 801-809, 2024 04 02.
Article in English | MEDLINE | ID: mdl-38334390

ABSTRACT

OBJECTIVES: To investigate the genomic diversity and ß-lactam susceptibilities of Enterococcus faecalis collected from patients with infective endocarditis (IE). METHODS: We collected 60 contemporary E. faecalis isolates from definite or probable IE cases identified between 2018 and 2021 at the University of Pittsburgh Medical Center. We used whole-genome sequencing to study bacterial genomic diversity and employed antibiotic checkerboard assays and a one-compartment pharmacokinetic-pharmacodynamic (PK/PD) model to investigate bacterial susceptibility to ampicillin and ceftriaxone both alone and in combination. RESULTS: Genetically diverse E. faecalis were collected, however, isolates belonging to two STs, ST6 and ST179, were collected from 21/60 (35%) IE patients. All ST6 isolates encoded a previously described mutation upstream of penicillin-binding protein 4 (pbp4) that is associated with pbp4 overexpression. ST6 isolates had higher ceftriaxone MICs and higher fractional inhibitory concentration index values for ampicillin and ceftriaxone (AC) compared to other isolates, suggesting diminished in vitro AC synergy against this lineage. Introduction of the pbp4 upstream mutation found among ST6 isolates caused increased ceftriaxone resistance in a laboratory E. faecalis isolate. PK/PD testing showed that a representative ST6 isolate exhibited attenuated efficacy of AC combination therapy at humanized antibiotic exposures. CONCLUSIONS: We find evidence for diminished in vitro AC activity among a subset of E. faecalis IE isolates with increased pbp4 expression. These findings suggest that alternate antibiotic combinations against diverse contemporary E. faecalis IE isolates should be evaluated.


Subject(s)
Endocarditis, Bacterial , Endocarditis , Gram-Positive Bacterial Infections , Humans , Ceftriaxone/pharmacology , Ceftriaxone/therapeutic use , Enterococcus faecalis , Ampicillin/pharmacology , Ampicillin/therapeutic use , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Endocarditis, Bacterial/drug therapy , Endocarditis, Bacterial/microbiology , Endocarditis/drug therapy , Microbial Sensitivity Tests , Gram-Positive Bacterial Infections/drug therapy , Gram-Positive Bacterial Infections/microbiology , Drug Therapy, Combination
20.
Eur J Clin Microbiol Infect Dis ; 43(5): 1013-1016, 2024 May.
Article in English | MEDLINE | ID: mdl-38416289

ABSTRACT

We report a clinical case of a child with an invasive pneumococcal disease caused by two different pneumococcal serotypes that belonged to different sequence types. She was a 15-month-old girl with pneumonia and pleural effusion in which S. pneumoniae colonies with different morphologies grew, one from the blood culture (characteristic greyish appearance) and the other from the pleural fluid (mucoid appearance). The isolate from blood was serotype 22 F (ST698/CC698/GPSC61), while the isolate from the pleural fluid was serotype 3 (ST180/CC180/GPSC12). The patient fully recovered after treatment with intravenous ampicillin followed by oral amoxicillin.


Subject(s)
Anti-Bacterial Agents , Serogroup , Streptococcus pneumoniae , Humans , Streptococcus pneumoniae/isolation & purification , Streptococcus pneumoniae/classification , Streptococcus pneumoniae/genetics , Female , Infant , Anti-Bacterial Agents/therapeutic use , Pneumococcal Infections/microbiology , Pneumococcal Infections/drug therapy , Pneumococcal Infections/diagnosis , Pleural Effusion/microbiology , Amoxicillin/therapeutic use , Ampicillin/therapeutic use , Pneumonia, Pneumococcal/microbiology , Pneumonia, Pneumococcal/drug therapy , Pneumonia, Pneumococcal/diagnosis , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL